Transcript of "RAVI DHAR, M.D. OFFICE ADDRESS: Division of Gastroenterology ..."
RAVI DHAR, M.D.OFFICE ADDRESS:Division of GastroenterologyHarper Hospital3990 John RDetroit, Michigan 48201Telephone: (313) 745-8601EDUCATION:1968 - 1970 Pre-Medical, S.P. College, Srinagar, Kashmir, India1970 - 1975 M.B.B.S., Government Medical College, Srinagar, Kashmir, IndiaTRAINING:1976 Internship, S.M.H.S. Hospital, Srinager, Kashmir, India1977 Residency, Pediatrics, Childrens Hospital, Srinagar, Kashmir, India1978 Diploma in Child Health, Government Medical College, Patiala, India1979 - 1980 Internship, Pediatrics, Childrens Hospital, Wayne State University School of Medicine, Detroit, Michigan1980 - 1981 Internship, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan1981 - 1983 Residency, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan1983 - 1985 Fellowship, Department of Internal Medicine, Division of Gastroenterology, Wayne State University School of Medicine, Detroit, Michigan
Ravi Dhar, M.D.Curriculum VitaePage 2FACULTY APPOINTMENTS: Consultations Attending, Harper Hospital (2 months). Gastroenterology Consultations Attending, Hutzel Hospital (4 months).1986 - 1987 Instructor of Medicine, Department of Internal Medicine, Division of Gastroenterology, Wayne State University School of Medicine, Detroit, Michigan1987 - 1988 Gastroenterology Consultations Attending, Veterans Administrative Hospital (7 months). Gastroenterology Consultations Attending, Grace Hospital (6 months).1987 - 1988 Instructor of Medicine, Full-Time Affiliate, Department of Internal Medicine, Division of Gastroenterology, Veterans Administration Medical Center, Allen Park, Michigan1988 - 1990 Instructor of Medicine, Department of Internal Medicine, Division of Gastroenterology, Wayne State University School of Medicine, Detroit, Michigan1988 - Present Gastroenterology Consultations Attending, Harper Hospital (4 months).1990 - Present Assistant Professor (Clinician-Educator) of Medicine, Department of Internal Medicine, Division of Gastroenterology, Wayne State University School of Medicine, Detroit, Michigan
Ravi Dhar, M.D.Curriculum VitaePage 3HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS:1983 Attending Physician, Detroit Receiving Hospital, Detroit, Michigan. February through June.1983 Emergency Room Physician, Harper-Grace Hospitals, Harper Division, Detroit, Michigan. February through June.1985 - 1986 Private practice, on staff Cottage and Hutzel Hospitals, and part-time teaching activities at Veterans Administration Medical Center in Allen Park, Michigan1989 - 1992 Director, GI Ambulatory Care, Harper Hospital, Detroit, Michigan1995 - 2000 Director, Clinical Operation, Division of Gastroenterology1995 - 2000 Member of C.O.C. (Clinical Operations Committee)2000 - 2001 Member of P.O.A.C. (Practice Operations Advisory Committee)2000 - Present Medical Director, Harper Professional Building, Suite #917, Detroit, MI2001 - Present Member, WSU Academic Senate2001 - Present Member, Budget Sub-committee, F.A.S.MAJOR PROFESSIONAL SOCIETIES:Midwest Gut ClubDetroit Gastroenterological SocietyAmerican College of Gastroenterologists, FellowAmerican Association of the Study of Liver DiseasesLICENSURE AND BOARD CERTIFICATION:Internal Medicine - Board EligibleLicensure - State of Michigan - 044147Ravi Dhar, M.D.
Curriculum VitaePage 4SERVICE:Patient Care:1985 - 1987 Gastroenterology Endoscopy Attending, Veterans Administrative Hospital.1987 - 1987 Gastroenterology Consultations Attending, Detroit Receiving Hospital (4 months).1987 - 1996 Gastroenterology Clinic, Monday afternoon and Thursday afternoon, University Health Center1987 – Present Gastroenterology Consultant, Harper Hospital Gastroenterology Consultant, Grace Hospital Gastroenterology Consultant, Detroit Receiving Hospital Gastroenterology Consultant, Hutzel Hospital1994 - 1995 Gastroenterology Clinic, Tuesday afternoon, Hutzel Warren1994 - 1996 Ambulatory Care, Grace Ambulatory Surgery Center, Southfield1994 - 1997 Gastroenterology Clinic, Tuesday morning, Southfield Clinic1997 Gastroenterology Clinic, MHCC Clinic, Detroit1996 - 2000 Gastroenterology Clinic, Tuesday afternoon, Wyandotte1996 – 2002 Gastroenterology Clinic, Monday afternoon and Wednesday morning, Harper Professional Building2002 – Present Gastroenterology Clinic, alternate Friday morning, Harper Professional Bldg1998 - Present Gastroenterology Clinic, Tuesday morning, Harper Professional Bldg.Professional Consultation: Public Media Presentation, Alternative and Complimentary Magazine “Colonics” with David Holzman, June 18, 1998.Ravi Dhar, M.D.
Curriculum VitaePage 5Hospital Committees:1988 - 1992 Chairman, Quality Assurance Committee, Department of Medicine, Grace Hospital1995 - 2000 Clinical Operations Committee, Harper Hospital2000 – Present Member P.O.A.C. (Practice Operations Advisory Committee)2001 - Present Member, WSU Academic Senate2001 - Present Member, Budget Sub-committee, F.A.S.TEACHING:Years at Wayne State University - (1986 - Present)Years at other colleges/universities -1985 - 1986 Part-time teaching activities at Veterans Administration Medical Center, Allen Park, MI.Courses taught at Wayne State University in last five years -1991 Physical Diagnosis Coordinator for Year II, Grace Hospital1992 Physical Diagnosis Coordinator for Year II, Grace Hospital a. Lecturer, Year II Medical Students. b. Lecturer, Year III, Gastroenterology Teaching Program (Quarterly). c. Physical Diagnosis, Medical Students.Teaching RoundsGeneral Medicine (Resident & Student Teaching) 1-4 months per year.Gastroenterology Teaching with Fellows 8 months per year.Ravi Dhar, M.D.Curriculum Vitae
Page 6GRANT SUPPORT:4/88 - 4/90 Principal Investigator, Pharmaceutical Product Development, Inc., "A Comparison of Ranitidine 300 mg HS, Ranitidine 300 mg BID, Ranitidine 300 mg TID, and Ranitidine 300 mg QID in the Treatment of Duodenal Ulcer Disease", $5,730.00.4/88 - 4/90 Principal Investigator, Pharmaceutical Product Development, Inc., "A Comparison of Ranitidine 150 mg and Placebo Administered at Bedtime for Maintenance of Recurrent Benign Gastric Ulcers", $70,000.00.9/88 - 9/90 Principal Investigator, Pfizer, Inc., "A Randomized Comparative Multicenter Trial of Fluconazole and Ketoconazole in the Treatment of Esophageal Condidiasis in Immunocompromised Patients", $105,155.00.3/93 - 3/95 Principal Investigator, Janssen Research Foundation, "Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis", $47,400.00.6/93 - 6/95 Principal Investigator, Glaxo Incorporated, "A Randomized, Double-Blind, Placebo-controlled, Multicenter Study or Oral GR122311X Compared with Ranitidine and GR88502X for the Prophylaxis of Nonsteroidal Anti- inflammatory Drug-associated Gastric or Duodenal Ulcers in Patients with Osteo- or Rheumatoid Arthritis and Without a History of Gastric or Duodenal Ulcers", $22,455.00.8/96 - 7-99 Co-Principal Investigator, Merck & Co., Inc., “A Multi clinic, Double-Blind, Randomized, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of L-743,872 vs. Amphotericin B in the Treatment of Candidal Esophagitis Infections in Adults”, $ 4,000.00.8/96 - 7-99 Co-Principal Investigator, Merck & Co., Inc., “A Multi clinic, Double-Blind, Randomized, Comparative Dose-Response Study to Evaluate the Safety, Tolerability, and Efficacy of L-743,872 vs. Amphotericin B in the Treatment of Fluconazole Unresponsive Oropharyngeal and Esophageal Candidasis in Adults”, $4,000.00.11/96 - 99 Co-Principal Investigator, Merck & Co., Inc., “ An Open, Serial-Panel, Multiple- Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L- 743,872 in Patients With Candida Esophagitis"” $4,000.00.Ravi Dhar, M.D.Curriculum VitaePage 7
11/96 - 99 Co-Principal Investigator, Merck & Co., Inc., “A Multi clinic, Double-Blind, Randomized, Comparative Dose-Response Study to Evaluate the Safety, Tolerability, and Efficacy of MK-0991 vs. Amphotericin B in the Treatment of Oropharyngeal and Esophageal Candidiasis in Adults” $4,000.00.1/99 – 6/02 CO-PI (PI: R. Murthy) “Comparison of Intron A plus revetol administered by three different regimens for the treatment of patients with chronic hepatitis C not previously treated with interferon” (Jan 99-June 2002 – 100 pts x 1000 = $100,000)6/00 - 6/05 CO PI (PI: M. Ehrinpreis) “Phase II study of long term PEG Intron for patients who have failed to respond to revetron/interferon with advanced fibrosis and cirrhosis secondary to hepatitis C” (June 2000 – June 2005 ___pts x 2000 = $___)7/00 – 7/02 CO-PI (PI: F. Siddiqui) START “Standard therapeutic assessment of rebvetron trial” (July 2000 – July 2002 – 5 pts x 1000 = $5000)10/00 -10/03 Principal Investigator: R. Dhar - Texas-RE-PEG “Randomized multicenter trial comparing induction PEG-Intron A plus Ribivarin vs PEG-Intron A plus Ribivarin in patients who have previously not responded or have relapsed following Intron-A based therapies for chronic hepatitis C, with maintenance therapy for patients who continue to remain non-responsive” (Oct 2000 – Oct 2003 – 30 pts x 1000 = $30,000)2003 – 2005 Idenix. A randomized, double-blind trial of LdT (Telbivudine) versus Lamivudine, in adults with compensated chronic hepatitis B. $11,000 Site P.I. Enrolled: 1. Co-PI2004 - 2006 Roche Laboratories, Inc. A prospective, randomized, open-label study evaluating the viral kinetics and pharmacokinetics of Pegasys plus copegus and PEG-Intron plus Rebetol in Interferon-naïve patients with chronic hepatitis C. $50,000. Co-PI, Enrolled: 6. Protocol Number ML17756B2005 – 2006 Idenix. A Phase IIb trial to evaluate the combination of pegylated interferon alfa plus valopicitabine (NM283) in treatment-naïve patients with chronic hepatitis C. Co-PI. $95,000. PI, #420266Ravi Dhar, M.D.Curriculum VitaePage 8
PUBLICATIONS:1. Dhar R, Gupta TP, Silverman AL, Kinzie JL, Desai TK and Luk GD. Screening for colorectal cancers and polyps. Wayne State University Bull Medicine, 1988.2. Ehrinpreis MN, Dhar R, and Narula A. Cimetidine-induced galactorrhea. Amer. J. Gastroenterology 84: 563-565, 1989.3. Jaszewski R, Calzada R, Dhar R. Persistence of gastric ulcers caused by plain aspirin or nonsteroidal anti-inflammatory agents in patients treated with a combination of cimetidine, antacids and enteric coated aspirin. Digestive Dis Sci 34(9):1361-1364, 1989.4. Meyerson S, Holtz, Ehrinpreis MN, and Dhar R. Small bowel obstruction during pregnancy. American Journal of Gastroenterology 90:299-302, 1995.5. Richard Jaszewski, Ahmed Khan, Fazlul H. Sarkar, Omer Kucuk, Martin Tobi, Abbas Zagnoon, Ravi Dhar, Joseph Kinzie, Adhip P. N. Majumdar, Folic acid inhibition of EGFR- mediated proliferation in human colon cancer cell lines. Am. J. Physiol. 277 (Cell Physiol. 46): 1999.6. Nagothu KK, Jaszewski R, Moragoda L, Rishi A, Finkenauer R, Tobi M, Naumoff J, Dhar R, Ehrinpreis MN, Kucuk O, Majumdar A. Folic acid mediated attenuation of loss of DCC tumor suppressor gene in the colonic mucosa of patients with colorectal adenomas. Cancer Detection and Prevention, May, 2003.BOOKS AND CHAPTERS:1. Silverman AL, Desai TK, Dhar R, Ehrinpreis MN, Kinzie JL, and Luk GD. Clinical features and detection of colorectal cancer. Gastroenterology Clin. N. Amer. 17:713-725, 1988.ABSTRACTS:1. Conteas CC, Laine L, DeBruin M, and Dhar R. Management of Esophageal Candidiasis in AIDS Patients: Fluconazole vs. Ketaconazole. Management of Fungal Infections, Montreal, Canada, July 1990.2. Harrison M, Hart J, Dhar R, Conteas C, Golwala R, Madon S, Idlidi O, and McGuire N. Granulomatous Mass Presenting as an Obstructive Lesion in the Rectum. Regional ACP, Traverse City, 1990.Ravi Dhar, M.D.Curriculum VitaePage 9
ABSTRACTS Cont.:3. Simoff M, Lundstrom T, Dhar R, Khatib R, and McGuire N. AIDS Without Detectable HIV Antibody by Both ELISA and Western Blot. Regional ACP, Traverse City, 1990.4. Meyerson S, Holtz T, Ehrinpreis MN, and Dhar R. Small Bowel Obstruction During Pregnancy. American Journal of Gastroenterology 88(19):1593, 1993. Presented at ACG National Meeting, New York, October, 1993.5. Mandviwala A, Lesser B, Dhar R, Piskorowski T, Haapaniemi J, and Weyhing B. Massive Pleural Effusion Attributed to Cirrhosis Without Ascites. Presented at American College of Physicians Meeting, Traverse City, 1994.6. Dhar JP, Dhar R, and Mutchnick MG. Hepatitis C and auto immunity. Amer Coll Rheumatol 441, 1994.7. Naylor, P. H., Podzorski, R., Dhar, R., Ehrinpreis, M. N., Kinzie, J. L. Kinzie, Siddiqui, F. A., Mutchnick, M. G.: Two Laboratory methods for measuring serum HCV RNA in patients with hepatitis C are equal with respect to determining and predicting end-of- treatment response to Interferon therapy. Antiviral Therapies: Volume 4 (Supplement 4), December 12-16, 1999.8. Wiedler, N, Naylor, PH, Patel, C, Chilukuri, S. , Mendu, S, Janisse, J, Dhar, R, Ehrinpreis, M, Kinzie, JL, Siddiqui, F, Turner, J, Mutchnick, MG,: Demographical and biochemical influences on quality of life scores in urban patients with Hepatitis C. Gastroenterology 118: A995, 2000 (Presented at DDW, San Diego, CA. 05/22/00).9. Khalifa-Al Saleh, A, Naylor, PH, Kinzie, JL, Ehrinpreis, MN, Siddiqui, F, Dhar, R, Turner, JR, and Mutchnick, MG:, End of treatment response (ETR) to Intron A monotherapy in chronic hepatitis C is similar in patients with normal and elevated ALT. Antiviral10. Therapy 5, C190, 2000 (Presented at 10th Int’l Symposium on Viral Hepatitis and Liver Disease, Atlanta, GA, April 10, 2000).11. Alawad, G., Naylor, PH, Hemacha, A., Jamma, K., Wielder, N., Kinzie, JL., Ehrinpreis, MN, Dhar, R., Siddiqui, F., Mutchnick, MG. Differences in side effect profiles and response to combination ribivarin and interferon alpha 2b (IFN) therapy between Caucasians and African Americans with chronic hepatitis C. Hepatology 32 A 835, 2000Ravi Dhar, M.D.Curriculum VitaePage 10
ABSTRACTS Cont.:12. Naylor, PH., Meja, L., Kinzie, JL., Ehrinpreis, MN, Dhar, R., Siddiqui, F., Turner, JR., Mutchnick, MG., Tumor necrosis factor alpha and chronic hepatitis C: lower serum levels in African Americans as compared to Caucasians. Hepatology 32 A406, 2000.13. Naylor, PH., Kinzie, JL., Ehrinpreis, M.N., Siddiqui F. , Dhar, R. and Mutchnick, M.D.: Retreatment of interferon failures with combination therapy: log drop after 12 weeks of monotherapy predicts ETR to combination. Antiviral Therapy 6, C191, 2000 (Presented at the 10th Int’l Symposium on Viral Hepatitis and Liver Disease, Atlanta, GA, (April 10, 2000).14. Shahin G, Naylor PH, Mutchnick MG, Siddiqui FA, Turner JR, Dhar R, Murthy R, Ehrinpreis MN. Influence of hepatitis C infection on gallstone prevalence in urban patients. Hepatology 2001;34(4pt.2):565A.15. Siddiqui FA, Ehrinpreis MN, Naylor PH, Dhar R, Murthy R, Boag J, Mutchnick MG. Response to combination treatment in African-American patients with chronic hepatitis C is significantly lower compared to Caucasians. Hepatology 2001;34(4pt.2):581A.16. F. Siddiqui, Paul Naylor, Murray Ehrinpreis, Ravi Dhar, Ravi Murthy, Prasad Kulkarni, Julie Boag, Milton Mutchnick. Biochemical, histological and clinical comparisons between African-American and Caucasian patients with chronic hepatitis C in an urban population. Gastroenterology, April 2001, Vol.120, No 5. Suppl. 1, A365, Presented as poster at Digestive Disease Week, Atlanta, May 200117. Siddiqui FA, Ehrinpreis MN, Naylor PH, Dhar R, Murthy R, Boag J, Mutchnick MG. Response to combination treatment in African-American patients with chronic hepatitis C is significantly lower compared to Caucasians. Hepatology 2001;34(4pt.2):581A.18. Siddiqui FA, Naylor P, Ehrinpreis M, Dhar R, Murthy R, Mutchnick M. African- Americans with chronic hepatitis C respond poorly to interferon/ribavirin combination treatment even when induction regimens are used. Gastroenterology 2002;123(1suppl.1):77A (T1402).19. Siddiqui F, Ehrinpreis M, Singh A, Dhar R, Murthy R, Mutchnick M. Prevalence of chronic hepatitis C infection in patients with hepatocellular carcinoma in an inner city population. Hepatology 2002;36(4pt.2):703A.Ravi Dhar, M.D.Curriculum VitaePage 11
ABSTRACTS Cont.:20. Lawitz E, Cantu N, Becker S, Dhar R, Li J, Natrajan S, Gordon S, Davis M, Nader P, Holtzmuller K, Rosenfield T, Monsour H. Pegylated Interferon Alfa 2b (PEG-IFN) and Ribavirin for Hepatitis C Patients Who Were Nonresponders to Previous Therapy. Gastroenterology 2002;123(1suppl.1):80 (T1402)21. Zalewska I, Siddiqui F, Ehrinpreis, Dhar R, Murthy R, Ranieri L, Janisse J, Mutchnick M. African Americans Failing Treatment with Interferon Monotherapy for Chronic Hep C Less Likeley to Achieve Sustained Response to Subsequent Retreatements Compared to Caucasians. Gastroenterology; 2003;124;4: (T1278)22. Lawitz EJ, Bala NS, Becker S, Brown G, Davis M, Dhar R, Ganeshappa KP, Gordon S, Holtzmuller K, Jeffries M, Jianjun L, Monsour H, Nader P, Rosenfield T, Tolman K, Kadakia S, Alamoa Study Group. Pegylated Interferon Alfa 2b and Rbavirin for Hepatitis C Patients Who Were Nonresponders to Previous Therapy. Gastroenterology, 2003;124;4:505A. (T1293)23. Pawa S, Ehrinpreis M, Mutchnick M, Dhar R, Siddiqui F. Percutaneous liver biopsy in chronic hepatitis C patients with End Stage Renal Disease is safe. Gastroenterology April 2004 Vol 126, No. 4, Suppl 2 M1220, 719.24. Pawa S, Mutchnick M, Ehrinpreis M, Dhar R, Greer J, Siddiqui F. Patients with chronic hepatitis C and chronic renal insufficiency or end stage renal disease respond poorly to Interferon monotherapy. Hepatology, October 2004, Vol 40, No. 4, Suppl. 1:332A.25. A. Khan, M. Mutchnick, M. Ehrinpreis, R. Dhar, F. Siddiqui. African-Americans with Genotype-1 with Chronic Hepatitis C Respond Poorly to Pegylated-Interferon and Ribavirin Combination Treatment as Compared to Caucasians. American Journal of Gastroenterology, September 2005, Vol 100, No. 9, Suppl 311.26. Perez NE, Maryala S, Seren S, Feng J, Pansare V and Dhar R. Metastatic Prostate Cancer Presenting as Mediastinal Lymphadenopathy Identified by Endoscopic Ultrasound with Fine Needle Aspiration. Am J Gastroenterol 2006;101(s2):S235, ACG Abstract #566.Ravi Dhar, M.D.Curriculum VitaePage 12
Letter to the Editor 1. J. Feng, M. Al-Abbadi, U. Kodali, R. Dhar. Cytologic Diagnosis of Gastric Linitis Plastica by Endoscopic Ultrasound Guided Fine-Needle Aspiration. Diagnostic Cytopathology, Vol. 34, No. 2., 177-179. 2006PRESENTATIONS:1. "Importance of the Digestive System", Holly Area Senior Center, Holly, Michigan, March 22, 1994.2. OHEP Internal Medicine Board Review Course, Northfield Hilton, Troy, Michigan, June 9, 1994.3. "Importance of the Digestive System", Waterford Senior Center, Waterford, Michigan, June 20, 1994.4. “Approach and Management of Diverticulosis”, Gastroenterology & Hepatobiliary Diseases for Internists & Gastroenterologists, Mackinac Island, MI , September 1996.5. “Approach to the Patient with Diverticulosis”, Medicine Ground Rounds, Harper Hospital, Detroit, MI, January 1997.6. New Pharmacological Advances, In The Treatment of Irritable Bowel Syndrome, Flushing, MI, August 8, 20007. New Pharmacological Advances, In The Treatment of Irritable Bowel Syndrome, Detroit, MI, September 8, 20008. Acid Peptic Disease, Troy, MI., September 2003.9. F.Siddiqui, M.Ehrinpreis, R.Dhar, M.Mutchnick. Demographics of patients with chronic hepatitis C in a large urban medical center. Presented at the Raymond Murphy African-American Health conference September 2005Ravi DharCurriculum VitaPage 13
Presented Internationally:A. Khan, M. Mutchnick, M. Ehrinpreis, R. Dhar, F. Siddiqui. African-Americans withGenotype-1 with Chronic Hepatitis C Respond Poorly to Pegylated-Interferon andRibavirin Combination Treatment as Compared to Caucasians. . Presented at theAmerican College of Gastroenterology meeting in Honolulu, Hawaii October 2005F. Siddiqui, R. Dhar, M.Mutchnick Prevalence of Chronic Hepatitis C Infection In Patientswith Hepatocellular Carcinoma in a Large Urban Medical Center Presented at HEP DARTin Hawaii, December 2005